12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

rFIXFc regulatory update

Biogen Idec said FDA accepted for review a BLA for rFIXFc to treat hemophilia B. Biogen Idec said the application was submitted during 4Q12; a standard review would place the PDUFA date in 4Q13, though a specific date is not disclosed. In 2007,...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >